Question explored with the scientific record
the role of tamiflu in flu
The short version: oseltamivir shortens flu symptoms by about a day, but the evidence for preventing serious complications is thin and comes from manufacturer-funded trials.
The question is whether oseltamivir is worth taking for a person with influenza. The evidence says it modestly shortens symptoms. In adults, a meta-analysis of 11 trials (4,769 participants) found it reduced symptom duration by about 21 to 25 hours, but did not convincingly reduce hospitalizations or most complications [2]. In children, one trial showed a 36-hour reduction in illness duration [4]. The effect depends on starting treatment early: within 24 hours of symptoms, household transmission dropped from 8.7% to 4.7% [1]. The drug also causes nausea in 12% and vomiting in 10% of adults [5].
The evidence base has serious problems. The 2012 meta-analysis [2] included 8 unpublished Roche trials alongside 3 published ones, meaning the manufacturer controlled most of the data. The reduction in pneumonia was small and inconsistent: in the lab-confirmed subgroup it was 0.9%, but in the overall group it was not statistically significant [2]. The one death reported was in the placebo group [2]. No trial compared vaccinated to unvaccinated people, and the longest follow-up was only a few weeks. The Cochrane review cited in the evidence notes that robust trials in high-risk patients are unlikely because CDC and WHO have already endorsed the drug, making randomization difficult [16].
| Outcome | Oseltamivir | Placebo | Difference |
|---|---|---|---|
| Symptom duration (adults) | ~97.5 hours | ~122.7 hours | -25.2 hours [22] |
| Symptom duration (children) | 101 hours | 137 hours | -36 hours [4] |
| Hospitalization (adults) | 0.1% absolute risk difference | - | Not significant [2] |
| Pneumonia (lab-confirmed) | 0.9% absolute risk reduction | - | Borderline significant [2] |
| Nausea | 12% | 4% | +8% [5] |
| Vomiting | 10% | 3% | +7% [5] |
My call: oseltamivir shortens symptoms by roughly a day if started within 48 hours, but the evidence for preventing hospitalization or death is weak and comes from manufacturer-controlled trials. Confidence: moderate for symptom reduction, low for complication prevention.
Sources examined 25
-
Does Treatment with Oseltamivir Prevent Transmission of Influenza to Household Contacts?
This study analyzes the effect of oseltamivir treatment on symptom duration, viral shedding, and household transmission of influenza, suggesting that early treatment can reduce transmission rates among household contacts.
DOI: 10.1086/650459 -
Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials
A comprehensive meta-analysis of published and unpublished randomized trials showing oseltamivir modestly reduces influenza symptom duration in adults but does not convincingly reduce hospitalization or most complications.
DOI: 10.1093/fampra/cms059 -
Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial
This study evaluates the efficacy of oseltamivir treatment initiated within 5 days of symptom onset in reducing the duration of influenza illness and virus shedding in a low-income urban setting in Bangladesh, finding significant benefits when treatment is started within 48 hour…
DOI: 10.1016/S1473-3099(13)70267-6 -
Oral oseltamivir treatment of influenza in children
This study demonstrates that oral oseltamivir treatment significantly reduces the duration and severity of influenza symptoms in children aged 1 to 12 years, when administered within 48 hours of symptom onset.
DOI: 10.1097/00006454-200102000-00002 -
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial
This study demonstrates that oseltamivir significantly reduces the duration and severity of influenza symptoms in healthy adults when administered within 36 hours of symptom onset, compared to placebo.
DOI: 10.1016/s0140-6736(00)02288-1 -
Oseltamivir
This study evaluates the efficacy and safety of oseltamivir, an oral prodrug of GS4071, in treating and preventing influenza A and B infections, demonstrating significant reductions in symptom duration and severity when administered early.
DOI: 10.2165/00003495-199958050-00007 -
A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population
This multicentre, randomized, controlled trial evaluates the efficacy and safety of oseltamivir in treating influenza among high-risk Chinese patients with chronic respiratory or cardiac diseases, demonstrating significant reductions in symptom duration and severity, as well as …
DOI: 10.1185/030079906X80297 -
A Meta-Analysis of Laninamivir Octanoate for Treatment and Prophylaxis of Influenza
Laninamivir octanoate offers comparable fever and symptom relief to oseltamivir and zanamivir for treating influenza and provides effective post-exposure prophylaxis versus placebo, but may prolong fever in H3N2 infections, with peramivir potentially superior for fever alleviati…
DOI: 10.3851/imp3189 -
Oseltamivir: a clinical and pharmacological perspective
This study evaluates the pharmacodynamics, pharmacokinetics, efficacy, and safety of oseltamivir, a neuraminidase inhibitor, in the treatment and prevention of influenza A and B infections.
DOI: 10.1517/14656566.2.10.1671 -
Oseltamivir
This review evaluates the efficacy, pharmacodynamics, pharmacokinetics, and tolerability of oseltamivir, a neuraminidase inhibitor, in the treatment and prophylaxis of influenza A and B, highlighting its significant impact on reducing illness duration and severity when administe…
DOI: 10.2165/00003495-200161020-00011 -
Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza
This review evaluates the accuracy of diagnostic tests and the efficacy of antiviral treatments for influenza in children, highlighting the need for improved clinical diagnosis and further studies on antiviral resistance.
DOI: 10.1097/01.inf.0000050458.35010.b6 -
Community Transmission of Pandemic Influenza A (H1N1) in China
This study investigates a community outbreak of pandemic influenza A (H1N1) in China, highlighting the effectiveness of oseltamivir in controlling the outbreak and the genetic stability of the virus strains involved.
DOI: 10.1086/655020 -
Differences in antibiotic and antiviral use in people with confirmed influenza: a retrospective comparison of rapid influenza PCR and multiplex respiratory virus PCR tests
Rapid influenza PCR testing reduced unnecessary antibiotic use and increased appropriate oseltamivir use in high-risk influenza patients, without affecting overall hospital length of stay, compared with standard multiplex PCR testing in a retrospective NSW hospital cohort.
DOI: 10.1186/s12879-021-06030-w -
Evaluation of the use of oseltamivir prophylaxis in the control of influenza outbreaks in long-term care facilities in Alberta, Canada: a retrospective provincial database analysis
This study evaluates the impact of oseltamivir prophylaxis on the management of influenza outbreaks in long-term care facilities in Alberta, Canada, finding that timely administration can shorten outbreak duration but has limited effect on hospitalization and influenza-like illn…
DOI: 10.1136/bmjopen-2016-011686 -
Influenza A-associated severe pneumonia in hospitalized patients: Risk factors and NAI treatments
A multicenter, retrospective study in Zhejiang, China identifies host risk factors for developing influenza A-associated severe pneumonia and evaluates neuraminidase inhibitor (NAI) dosing, finding male gender, chronic pulmonary disease, and diabetes as risk factors, with double…
DOI: 10.1016/j.ijid.2020.01.017 -
Neuraminidase Inhibitors and Influenza Infection
A correspondence debating the evidence for neuraminidase inhibitors in influenza, arguing that randomized trials in high‑risk patients are unlikely due to ethical considerations, acknowledging observational data suggesting potential benefits, weighing adverse events, and calling…
DOI: 10.1001/jamainternmed.2016.0013 -
Afebrile Presentation in COPD Patients with Influenza A: A Risk Factor for Prolonged Viral Shedding
Prolonged influenza A shedding in oseltamivir-treated inpatients is independently predicted by older age, lymphopenia, cerebrovascular disorders, immunosuppression, delayed antiviral therapy, and fungal coinfection, with COPD patients frequently afebrile and showing low lymphocy…
DOI: 10.2147/COPD.S559844 -
Influenza: current evidence and informed predictions
A comprehensive review of influenza biology, epidemiology, diagnosis, antiviral therapies, vaccination strategies (including inactivated and live attenuated vaccines), safety considerations, and future pandemic preparedness, synthesizing current evidence on vaccine efficacy, ant…
DOI: 10.1586/14760584.3.4.443 -
Cost-Effectiveness Analysis of Influenza Treatments in Japan Using a Transmission Model: The Impact of Baloxavir and Oseltamivir Shares
A two-model analysis (dynamic SEIR transmission model plus static cost-effectiveness tree) in Japan shows that increasing baloxavir share over oseltamivir among people aged 12+ is cost-saving and more effective than a lower baloxavir share, with substantial population-wide reduc…
DOI: 10.1007/s40121-025-01203-5 -
Use of Antiviral Prophylaxis in Influenza Outbreaks in Long Term Care Facilities
This paper reviews initiation and discontinuation of antiviral prophylaxis for influenza A outbreaks in long-term care facilities, comparing amantadine with neuraminidase inhibitors (zanamivir and oseltamivir), and outlining practical dosing strategies, resistance considerations…
DOI: 10.1155/2000/246037 -
Comparison of Household Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study
This study compares household transmission rates of influenza virus from index patients treated with baloxavir marboxil versus neuraminidase inhibitors, finding that baloxavir marboxil significantly reduces transmission risk.
DOI: 10.1093/cid/ciaa1622 -
Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials
This meta-analysis of randomized controlled trials demonstrates that oseltamivir treatment significantly accelerates symptom alleviation and reduces the risk of lower respiratory tract complications in adults with influenza, while increasing the incidence of nausea and vomiting.
DOI: 10.1016/S0140-6736(14)62449-1 -
Reduction in Sympathetic Nerve Activity as a Possible Mechanism for the Hypothermic Effect of Oseltamivir, an Anti‐influenza Virus Drug, in Normal Mice
This study investigates the hypothermic effects of oseltamivir and its active metabolite, oseltamivir carboxylate, in normal mice, suggesting that these effects are mediated through the depression of sympathetic nerve activity rather than neuraminidase inhibition.
DOI: 10.1111/bcpt.12058 -
Dihydrodibenzothiepine: Promising hydrophobic pharmacophore in the influenza cap-dependent endonuclease inhibitor
Discovery and SAR optimization of a carbamoyl pyridone influenza cap-dependent endonuclease (CEN) inhibitor, identifying dihydrodibenzothiepine as the key N-1 pharmacophore and (S)-13i as a potent lead that surpasses oseltamivir in a mouse model, ultimately leading toward baloxa…
DOI: 10.1016/j.bmcl.2020.127547 -
Cooperative anti-influenza activities of respiratory innate immune proteins and neuraminidase inhibitor
This study demonstrates that respiratory innate immune proteins—surfactant protein D (SP-D), surfactant protein A (SP-A), and glycoprotein 340 (gp340)—as well as mucins cooperatively inhibit influenza A virus in vitro, with oseltamivir-enhanced effects for SP-A and BAL fluid but…
DOI: 10.1152/ajplung.00365.2004